PDCD1 and cancer: Two clinical trials are in progress to determine whether re-purposed immunotherapies targeting the PD-L1 and PD-1 checkpoint pathway, originally developed to treat cancer patients, can be used to activate the immune system against HPV-infected cells (Table 2).